Emerging trends in the treatment of rapid cycling bipolar disorder: A selected review

Robert M. Post, Mark A Frye, Kirk D. Denicoff, Gabriele S. Leverich, Robert T. Dunn, Elizabeth A. Osuch, Andrew M. Speer, Gabriela Obrocea, Kamal Jajodia

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Recent evidence suggests that lithium therapy (even as supplemented by antidepressants and neuroleptics) is inadequate for the majority of patients with bipolar illness, and particularly those with rapid cycling. Valproate and carbamazepine have emerged as adjuncts and alternatives, but they, too, often require additional approaches with lithium, thyroid hormones, and other putative mood stabilizers, including nimodipine (and related dihydropyridine calcium channel blockers), lamotrigine, gabapentin, topiramate, and the atypical neuroleptics. Evaluating how these agents and the unimodal antidepressants are optimally applied and sequenced in the treatment of bipolar illness with its multiple subtypes, patterns and comorbidities will require much future investigation and the development of new methodological clinical trial approaches.

Original languageEnglish (US)
Pages (from-to)305-315
Number of pages11
JournalBipolar Disorders
Volume2
Issue number4
StatePublished - Dec 2000
Externally publishedYes

Fingerprint

Bipolar Disorder
Lithium
Antidepressive Agents
Antipsychotic Agents
Nimodipine
Carbamazepine
Calcium Channel Blockers
Valproic Acid
Thyroid Hormones
Comorbidity
Clinical Trials
Therapeutics
1,4-dihydropyridine
gabapentin
topiramate
lamotrigine

Keywords

  • Anticonvulsants
  • Calcium channel blockers
  • Carbamazepine
  • Gabapentin
  • Lamotrigine
  • Lithium
  • Nimodipine
  • Repeated transcranial magnetic stimulation (rTMS)
  • Tolerance
  • Valproate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Post, R. M., Frye, M. A., Denicoff, K. D., Leverich, G. S., Dunn, R. T., Osuch, E. A., ... Jajodia, K. (2000). Emerging trends in the treatment of rapid cycling bipolar disorder: A selected review. Bipolar Disorders, 2(4), 305-315.

Emerging trends in the treatment of rapid cycling bipolar disorder : A selected review. / Post, Robert M.; Frye, Mark A; Denicoff, Kirk D.; Leverich, Gabriele S.; Dunn, Robert T.; Osuch, Elizabeth A.; Speer, Andrew M.; Obrocea, Gabriela; Jajodia, Kamal.

In: Bipolar Disorders, Vol. 2, No. 4, 12.2000, p. 305-315.

Research output: Contribution to journalArticle

Post, RM, Frye, MA, Denicoff, KD, Leverich, GS, Dunn, RT, Osuch, EA, Speer, AM, Obrocea, G & Jajodia, K 2000, 'Emerging trends in the treatment of rapid cycling bipolar disorder: A selected review', Bipolar Disorders, vol. 2, no. 4, pp. 305-315.
Post RM, Frye MA, Denicoff KD, Leverich GS, Dunn RT, Osuch EA et al. Emerging trends in the treatment of rapid cycling bipolar disorder: A selected review. Bipolar Disorders. 2000 Dec;2(4):305-315.
Post, Robert M. ; Frye, Mark A ; Denicoff, Kirk D. ; Leverich, Gabriele S. ; Dunn, Robert T. ; Osuch, Elizabeth A. ; Speer, Andrew M. ; Obrocea, Gabriela ; Jajodia, Kamal. / Emerging trends in the treatment of rapid cycling bipolar disorder : A selected review. In: Bipolar Disorders. 2000 ; Vol. 2, No. 4. pp. 305-315.
@article{d476b347b987401e8994cb081fe5d371,
title = "Emerging trends in the treatment of rapid cycling bipolar disorder: A selected review",
abstract = "Recent evidence suggests that lithium therapy (even as supplemented by antidepressants and neuroleptics) is inadequate for the majority of patients with bipolar illness, and particularly those with rapid cycling. Valproate and carbamazepine have emerged as adjuncts and alternatives, but they, too, often require additional approaches with lithium, thyroid hormones, and other putative mood stabilizers, including nimodipine (and related dihydropyridine calcium channel blockers), lamotrigine, gabapentin, topiramate, and the atypical neuroleptics. Evaluating how these agents and the unimodal antidepressants are optimally applied and sequenced in the treatment of bipolar illness with its multiple subtypes, patterns and comorbidities will require much future investigation and the development of new methodological clinical trial approaches.",
keywords = "Anticonvulsants, Calcium channel blockers, Carbamazepine, Gabapentin, Lamotrigine, Lithium, Nimodipine, Repeated transcranial magnetic stimulation (rTMS), Tolerance, Valproate",
author = "Post, {Robert M.} and Frye, {Mark A} and Denicoff, {Kirk D.} and Leverich, {Gabriele S.} and Dunn, {Robert T.} and Osuch, {Elizabeth A.} and Speer, {Andrew M.} and Gabriela Obrocea and Kamal Jajodia",
year = "2000",
month = "12",
language = "English (US)",
volume = "2",
pages = "305--315",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "4",

}

TY - JOUR

T1 - Emerging trends in the treatment of rapid cycling bipolar disorder

T2 - A selected review

AU - Post, Robert M.

AU - Frye, Mark A

AU - Denicoff, Kirk D.

AU - Leverich, Gabriele S.

AU - Dunn, Robert T.

AU - Osuch, Elizabeth A.

AU - Speer, Andrew M.

AU - Obrocea, Gabriela

AU - Jajodia, Kamal

PY - 2000/12

Y1 - 2000/12

N2 - Recent evidence suggests that lithium therapy (even as supplemented by antidepressants and neuroleptics) is inadequate for the majority of patients with bipolar illness, and particularly those with rapid cycling. Valproate and carbamazepine have emerged as adjuncts and alternatives, but they, too, often require additional approaches with lithium, thyroid hormones, and other putative mood stabilizers, including nimodipine (and related dihydropyridine calcium channel blockers), lamotrigine, gabapentin, topiramate, and the atypical neuroleptics. Evaluating how these agents and the unimodal antidepressants are optimally applied and sequenced in the treatment of bipolar illness with its multiple subtypes, patterns and comorbidities will require much future investigation and the development of new methodological clinical trial approaches.

AB - Recent evidence suggests that lithium therapy (even as supplemented by antidepressants and neuroleptics) is inadequate for the majority of patients with bipolar illness, and particularly those with rapid cycling. Valproate and carbamazepine have emerged as adjuncts and alternatives, but they, too, often require additional approaches with lithium, thyroid hormones, and other putative mood stabilizers, including nimodipine (and related dihydropyridine calcium channel blockers), lamotrigine, gabapentin, topiramate, and the atypical neuroleptics. Evaluating how these agents and the unimodal antidepressants are optimally applied and sequenced in the treatment of bipolar illness with its multiple subtypes, patterns and comorbidities will require much future investigation and the development of new methodological clinical trial approaches.

KW - Anticonvulsants

KW - Calcium channel blockers

KW - Carbamazepine

KW - Gabapentin

KW - Lamotrigine

KW - Lithium

KW - Nimodipine

KW - Repeated transcranial magnetic stimulation (rTMS)

KW - Tolerance

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=0034574536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034574536&partnerID=8YFLogxK

M3 - Article

C2 - 11252642

AN - SCOPUS:0034574536

VL - 2

SP - 305

EP - 315

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 4

ER -